🔑 Key Definitions
Dopamine (DA): Monoamine neurotransmitter involved in movement, motivation, reward, and cognition
L-DOPA: Dopamine precursor used to treat Parkinson's disease; crosses blood-brain barrier
Nigrostriatal Pathway: Dopamine pathway from substantia nigra to striatum; degeneration causes Parkinson's
Mesolimbic Pathway: Dopamine pathway from VTA to nucleus accumbens and limbic areas; involved in reward and schizophrenia
L-DOPA: Dopamine precursor used to treat Parkinson's disease; crosses blood-brain barrier
Nigrostriatal Pathway: Dopamine pathway from substantia nigra to striatum; degeneration causes Parkinson's
Mesolimbic Pathway: Dopamine pathway from VTA to nucleus accumbens and limbic areas; involved in reward and schizophrenia
🧠 Dopamine Synthesis Pathway
- Phenylalanine: Essential amino acid from diet
- → Tyrosine: Converted from phenylalanine
- → L-DOPA: Tyrosine hydroxylase (rate-limiting enzyme)
- → Dopamine: DOPA decarboxylase removes carboxyl group
📊 Three Major Dopamine Pathways
- Nigrostriatal: Substantia nigra → Striatum; motor control; loss causes Parkinson's disease
- Mesolimbic: VTA → Nucleus accumbens/limbic; reward, motivation; overactivity linked to schizophrenia
- Tuberoinfundibular: Hypothalamus → Pituitary; inhibits prolactin release
📊 Receptors & Disorders
- D1 Receptors: Excitatory; increase cAMP
- D2 Receptors: Inhibitory; decrease cAMP; target of antipsychotic drugs
- Parkinson's Disease: DA deficiency in nigrostriatal pathway; treat with L-DOPA
- Schizophrenia: Excess DA activity in mesolimbic pathway; treat by blocking D2 receptors
📊 Dopamine Deactivation
- MAO (Monoamine Oxidase): Enzyme that breaks down dopamine inside neuron
- COMT (Catechol-O-Methyltransferase): Enzyme that breaks down dopamine in synaptic cleft
- Reuptake: DAT (dopamine transporter) pumps DA back into presynaptic terminal
💡 Exam Tips
- Remember synthesis: Phenylalanine → Tyrosine → DOPA → Dopamine
- Three pathways: Nigrostriatal (movement), Mesolimbic (reward), Tuberoinfundibular (hormones)
- Parkinson's = TOO LITTLE DA (nigrostriatal), Schizophrenia = TOO MUCH DA (mesolimbic)
- L-DOPA crosses blood-brain barrier, dopamine doesn't - that's why L-DOPA used as treatment
- D2 receptor blockers = antipsychotics (but can cause Parkinson-like side effects)
- MAO and COMT both break down DA - MAO inhibitors used as antidepressants